Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster viewing 01

30P - Investigation of KRAS G12C inhibitor JAB-21822 as a single agent and in combination with SHP2 inhibitor JAB-3312 in preclinical cancer models

Date

03 Dec 2022

Session

Poster viewing 01

Topics

Translational Research;  Targeted Therapy

Tumour Site

Non-Small Cell Lung Cancer;  Pancreatic Adenocarcinoma;  Colon and Rectal Cancer

Presenters

Peng Wang

Citation

Annals of Oncology (2022) 33 (suppl_9): S1441-S1444. 10.1016/annonc/annonc1121

Authors

P. Wang1, Q. Zheng1, D. Kang2, X. Sun3, S. Zhu4, Y. Wang2, W. Long5, Y. Lin4

Author affiliations

  • 1 Biology, Jacobio Pharmaceuticals Co., Ltd., 101111 - Beijing/CN
  • 2 Pharmacology, Jacobio Pharmaceuticals Co., Ltd., 101111 - Beijing/CN
  • 3 Translational Medicine, Jacobio Pharmaceuticals Co., Ltd., 101111 - Beijing/CN
  • 4 Translational Medicine, Jacobio (US) Pharmaceuticals, Inc., 02421 - Lexington/US
  • 5 Medicinal Chemistry And Hits Discovery, Jacobio Pharmaceuticals Co., Ltd., 101111 - Beijing/CN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 30P

Background

While the currently available KRASG12C-selective inhibitors including Sotorasib have shown promising efficacy, acquired resistance eventually occurred in most cancer patients following treatment. Blocking SHP2, one of critical upstream nodes, represents a rationalized strategy to overcome resistance. We have previously developed JAB-21822, a selective covalent KRASG12C inhibitor and JAB-3312, a selective allosteric SHP2 inhibitor, both of which have entered multiple clinical trials.

Methods

Cell growth inhibitory effect of JAB-21822 was evaluated in various human cancer cell lines, as well as Ba/F3 cells expressing different KRASG12C mutants with or without secondary point mutations that contribute to KRASG12C inhibitor resistance. Tumor growth inhibitory effect of JAB-21822 was also evaluated in cell line- and patient-derived xenografts. Using similar approaches, the effect of JAB-21822 in combination with JAB-3312 was evaluated in KRASG12C inhibitor-resistant tumor cells and xenograft models. Furthermore, RNA-seq was performed to identify genes with altered expression in KRAS12C inhibitor-resistant NCI-H358 cells compared to their parental counterparts. Expression of selected candidate genes were further confirmed by real-time PCR.

Results

As a single agent, JAB-21822 showed early potent antitumor effect both in vitro and in vivo. RNA-seq further identified potential genes involved in KRASG12C inhibitor resistance. Significantly, combination of JAB-21822 with JAB-3312 exerted synergistic effect in the KRASG12C inhibitor-resistant tumor cells and xenograft models tested.

Conclusions

JAB-21822 is a promising KRASG12C-targeting drug and, when combined with JAB-3312, can overcome adaptive resistance to KRASG12C inhibition. These preclinical data have provided rationale for our clinical trial featuring the two drugs combination in treating KRASG12C inhibitor-resistant cancer patients.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Jacobio Pharmaceuticals Co., Ltd.

Funding

AbbVie.

Disclosure

P. Wang, Q. Zheng, D. Kang, X. Sun, S. Zhu, Y. Wang, W. Long, Y. Lin : Financial interests, Personal, Full or part-time Employment: Jacobio Pharmaceuticals Co.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.